RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist. The company was founded on February 19, 2008 and is headquartered in Nagoya, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company